(Sharecast News) - Drugmaker Astrazeneca said on Tuesday that it has signed an exclusive licensing deal with Dizal Pharmaceutical for Zegfrovy, its non‑small cell lung cancer treatment, securing global rights to develop and commercialise the drug.
Zegfrovy has already received approval in the US and China for adults with locally advanced...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE